Tesamorelin typical research dosing
Across the available literature, Tesamorelin is most commonly administered at 1000–2000 mcg per dose, 1 time(s) per day, via subcutaneous injection. The FDA-approved clinical dose is 2 mg (2000 mcg) subcutaneously once daily. Some research protocols use 1 mg daily. Rotate injection sites to minimize local reactions.
Tesamorelin unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 1 mg Tesamorelin vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 1000 mcg | 1500 mcg | 2000 mcg |
|---|---|---|---|---|
| 1 mL | 1000 mcg/mL | 100.0 units | 150.0 units | 200.0 units |
| 2 mL | 500 mcg/mL | 200.0 units | 300.0 units | 400.0 units |
| 3 mL | 333 mcg/mL | 300.0 units | 450.0 units | 600.0 units |
| 5 mL | 200 mcg/mL | 500.0 units | 750.0 units | 1000.0 units |
Tesamorelin cycle length
Most reported Tesamorelin protocols run 26 weeks on, then 8 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
Tesamorelin half-life and timing
Tesamorelin has a half-life of approximately 0.43 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.